Sector News

Pfizer, BioNTech strike COVID-19 deal, commit multiple R&D sites to vaccine development

March 17, 2020
Life sciences

Pfizer has teamed up with BioNTech to co-develop and distribute a mRNA vaccine against COVID-19 outside of China. The partners plan to use multiple R&D sites in the U.S. and Germany to accelerate the progress of a vaccine that is due to begin clinical testing in humans by the end of April.

BioNTech and Pfizer have both referred to talks about a COVID-19 partnership in recent weeks, most recently yesterday when the German mRNA specialist issued a statement on the status of its vaccine and related deal-making. The latest advance in the partnering discussions clears BioNTech and Pfizer to immediately start working together on a vaccine against the novel SARS-CoV-2 coronavirus.

To initiate the alliance, Pfizer and BioNTech have executed a material transfer and collaboration agreement and agreed on a letter of intent covering the co-development and distribution of the vaccine, code-named BNT162, outside of China. Fosun Pharma is partnered on the vaccine in China.

The paperwork signed by BioNTech and Pfizer to date lacks details that ordinarily would be central to a co-development agreement, most notably the final financial terms of the relationship. However, with the number of COVID-19 cases rising rapidly in countries around the world, Pfizer and BioNTech have decided not to let the financial details hold up the collaboration.

Over the next few weeks, BioNTech and Pfizer will finalize the financial terms and details of how the development, manufacturing and commercialization will work. The execution of the collaboration agreement means a joint effort to push the vaccine forward will advance in parallel to those talks.

While full details of how the partnership will work are still being finalized, the broad plan is for Pfizer and BioNTech to commit resources at multiple R&D sites in the U.S. and Germany to the project. The involvement of Pfizer, a far larger company than BioNTech, could potentially unlock resources that accelerate the progress of the vaccine.

“We believe that by pairing Pfizer’s development, regulatory and commercial capabilities with BioNTech’s mRNA vaccine technology and expertise as one of the industry leaders, we are reinforcing our commitment to do everything we can to combat this escalating pandemic, as quickly as possible,” Mikael Dolsten, Pfizer’s chief scientific officer, said in a statement.

BioNTech expects to start testing the vaccine in humans late next month and already has capacity in place to produce materials for the global clinical trial. The partnerships with Fosun and Pfizer are intended to ensure the program retains momentum right through to commercial availability.

Having a vaccine in the clinic by late April would represent a fast turnaround by historical standards. Yet, the timeline puts BioNTech well behind another of the main mRNA companies, Moderna, which began testing its vaccine in healthy volunteers this week. Both companies have benefited from mRNA vaccine platforms that are faster than conventional ways of developing prophylactic shots.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).